N4BP2L2

Across TCGA pan-cancer cohorts, N4BP2L2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated N4BP2L2 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher N4BP2L2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated N4BP2L2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where N4BP2L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.786	0.888	.008	22	view →
LUAD	DFS	Median	All	0.824	0.514	.008	15	view →
LSCC	DFS	Quartile	II,III,IV	0.748	1.000	.008	7	view →
PDAC	OS	Tertile	II,III,IV	0.928	0.551	.017	5	view →
GBM	OS	Median	All	0.457	0.265	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

N4BP2L2–HNSC (OS)

Open the HNSC breakdown →